Selected article for: "receptor bind and viral genome"

Author: Der-Nigoghossian, Caroline; Ciolek, Alana; Chuich, Taylor
Title: Therapeutic Approach to Coronavirus Disease
  • Cord-id: 9w9hp35d
  • Document date: 2020_10_6
  • ID: 9w9hp35d
    Snippet: The global pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), was first identified in Wuhan, China, in December 2019. The viral genome was rapidly identified in order to develop diagnostic testing and therapeutic options. SARS-CoV2 is a single-stranded RNA-enveloped virus that uses its surface spike (S) protein to bind host cell’s angiotensin converting enzyme 2 (ACE2) receptor in the presence of host cell protease TMPRSS
    Document: The global pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), was first identified in Wuhan, China, in December 2019. The viral genome was rapidly identified in order to develop diagnostic testing and therapeutic options. SARS-CoV2 is a single-stranded RNA-enveloped virus that uses its surface spike (S) protein to bind host cell’s angiotensin converting enzyme 2 (ACE2) receptor in the presence of host cell protease TMPRSS2, a cofactor for virus entry [1]. The virus uses RNA-dependent RNA polymerase to synthesize RNA leading to viral assembly and exocytosis [2].

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and lopinavir ritonavir safety efficacy: 1
    • acute sars cov respiratory syndrome coronavirus and lopinavir ritonavir group: 1, 2
    • acute sars cov respiratory syndrome coronavirus and lopinavir ritonavir role: 1
    • acute sars cov respiratory syndrome coronavirus and lopinavir ritonavir safety efficacy: 1
    • adjunctive therapy and lopinavir ritonavir group: 1